California Desert Oasis Healthcare System (DOHC), has implemented Rimindi’s Respiratory Module for respiratory patient monitoring, based on data from Teva’s Digihaler System. Teva’s Digihaler, is the first and only smart inhaler system that can provide objective data to support improved asthma management.
Utilising Rimindi’s platform, COHC will identify patients with respiratory conditions that are appropriate candidates for treatment with one of Teva’s Digihaler products. Data from Teva’s Digihalers will then be available for providers to review through Rimindi’s Respiratory Module, giving a more complete view of a patient's condition and supporting in treatment decisions for patients with respiratory diseases such as chronic obstructive pulmonary disease (COPD) or asthma.
Longer term, outcomes will provide insights to inform the use of data from Teva’s Digihaler Systems and the module in U.S Health Systems. Furthermore, the platform can be used to monitor and manage larger populations, and capture data and insights for respiratory patients to improve disease management.
“Teva aims to be a leader in fusing technology and healthcare in order to help patients and their doctors more easily manage their treatment plans. Through collaborations with partners like Rimidi, we hope to improve the patient continuum of care, leading to a more cost-effective healthcare system,” said Manny Montalvo, Senior Vice President, Head of Digital Health & Innovation at Teva.
Click here to read the original news story.